Top in GI: New IBS guidelines, investigational eosinophilic esophagitis therapy
Click Here to Manage Email Alerts
The American College of Gastroenterology released new guidelines for the treatment of patients with irritable bowel syndrome. It was the top story in gastroenterology last week.
Another top story was about the FDA’s acceptance of a new drug application for an investigational eosinophilic esophagitis treatment.
Read these and more news in gastroenterology below:
ACG develops guidelines for treatment of IBS
The American College of Gastroenterology developed 25 clinical guidelines for the treatment of irritable bowel syndrome. Of these, nine focus on diagnostic testing and 16 focus on therapeutic options. Read more.
FDA accepts Takeda’s NDA, grants review for budesonide oral suspension
Takeda Pharmaceutical announced the FDA accepted its new drug application and granted priority review for TAK-721, an investigational therapy budesonide oral suspension intended for the treatment of eosinophilic esophagitis. Read more.
Topical budesonide may decrease endoscopic strictures after EMR, ESD
Recent data showed that topical budesonide may be linked to a decrease in endoscopic strictures after endoscopic mucosal resection or endoscopic submucosal dissection. Read more.
VIDEO: Pancreatic cancer should be considered a ‘medical emergency’
In this exclusive video, Monique van Leerdam, MD, and Matthias Löhr, MD, PhD, discuss the need for increased awareness about pancreatic cancer. Read more.
VIDEO: Early detection difficult in pancreatic cancer
Experts review the importance of early detection of pancreatic cancer. Read more.